Insider Selling: Mark Pruzanski Sells 25,000 Shares of Intercept Pharmaceuticals Stock (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) CEO Mark Pruzanski sold 25,000 shares of the stock on the open market in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $52.00, for a total transaction of $1,300,000.00. Following the transaction, the chief executive officer now directly owns 402,032 shares of the company’s stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on ICPT shares. Analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research note to investors on Wednesday, August 14th. They now have a $62.00 price target on the stock, up previously from $44.00. Separately, analysts at Needham & Company raised their price target on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $40.00 to $55.00 in a research note to investors on Tuesday, August 13th. They now have a “buy” rating on the stock. Finally, analysts at Wedbush reiterated an “outperform” rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research note to investors on Tuesday, August 13th. They now have a $67.00 price target on the stock, up previously from $65.00.
One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. Intercept Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $54.17.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 0.33% on Wednesday, hitting $54.53. The stock had a trading volume of 164,449 shares. Intercept Pharmaceuticals has a 1-year low of $17.96 and a 1-year high of $58.32. The stock has a 50-day moving average of $46.8 and a 200-day moving average of $39.87. The company’s market cap is $1.046 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.51) by $0.28. The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.40 million. On average, analysts predict that Intercept Pharmaceuticals will post $-2.30 earnings per share for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.